ClinicalTrials.gg
CompletedNCT03137784Updated Jan 16, 2019Results posted

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

A Phase 2/3 interventional study of NVA237 (glycopyrronium bromide) and Placebo in Asthma, sponsored by Novartis Pharmaceuticals. Completed at 21 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-01-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing glycopyrrolate in Asthma — 1 open to participants now, 1 under way, none of them phase 3. Glycopyrrolate · Asthma.

Enrollment
3rd of 10
148 · median 69
Started
2017
the only one that year
Phase 2/3
Only one
of the 10
Registered
6th of 10
by date
Lead sponsor
3 of 10
Novartis Pharmaceuticals

Among the 10 studies testing glycopyrrolate in Asthma, this one is the 3rd largest by enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 6th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 10 studies testing glycopyrrolate in Asthma is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing glycopyrrolate in Asthma, or all of them as a file.
02

Study summary

The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients

Read the detailed description

This study uses a randomized, double-blind, placebo controlled, 3-period cross-over clinical trial design. During a screening epoch patient eligibility will be assessed. The screening epoch will be followed by a 21-day Run-in epoch during which patients will continue their inhaled corticosteroids use but be withdrawn from LABA-treatment and switched to short-acting bronchodilator-rescue medication. After the Run-in period patients will be randomized to one of the 6 treatment sequences and enter the first 7-day study treatment period. Treatment period one is followed by a 10 to 14 days washout period after which patients begin the second 7-day treatment period which is then followed by a second 10 to 14 days washout period followed by the third 7-day treatment period. At the end of each treatment period spirometry will be performed to assess the primary endpoint in terms of trough FEV1. The study population will consist of approximately 144 patients with asthma who have been treated in a stable regimen of ICS/LABA for at least 4 weeks prior to screening.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma,
  • NVA237,
  • glycopyrronium bromide
  • allergic asthma,
  • allergy triggered asthma,
  • reactive asthma,
  • asthma attack,
  • difficulty breathing
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Male and female adult patients aged >= 18 or =\< 65 years
  • Patients with a diagnosis of asthma for a period of at least 1 year receiving daily treatment of ICS/LABA in a stable regimen for >= 4 weeks
  • Pre-bronchodilator of >= 50% and =\< 80% of the predicted normal value and an increase in FEV1 of 12% and >= 200 ml during reversibility testing

Key Exclusion Criteria:

  • Patients who have had an asthma exacerbation that required either treatment with systemic for at least 3 days, or an emergency room visit, or hospital treatment within 6 weeks prior to screening and patients with a history of life-threatening asthma attacks
  • Patients who have had a respiratory tract infection within 4 weeks prior to screening.
  • Patients who have smoked or inhaled tobacco products within the past 6 month of screening.
  • Patients with a history of chronic lung diseases other than asthma, including (but not limited to) , bronchiectasis, sarcoidosis, interstitial lung disease, cystic fibrosis, and tuberculosis (unless tuberculosis is confirmed as no longer active by imaging).
  • Patients on Maintenance Immunotherapy (desensitization) for allergies for at least 3 months prior to Run-in who are expected to change therapy throughout the course of the study.
  • Patients who during the Run-in period are shown to be intolerable to LABA withdrawal.
  • Patients who have discontinued LAMA therapy in the past (e.g. due to intolerance or perceived lack of efficacy).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
148 participants (actual)

Study arms

  • Other
    1(NVA237 50 ug/NVA237 25 ug/placebo)

    Treatment sequence: NVA 237 50 ug, 25 ug and placebo

    Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo

  • Other
    2(NVA237 50 ug/placebo/NVA237 25 ug)

    Treatment sequence: NVA 237 50 ug, placebo and 25 ug

    Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo

  • Other
    3 (NVA237 25 ug/NVA237 50 ug/placebo)

    Treatment sequence: NVA237 25 ug, 50 ug and placebo

    Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo

  • Other
    4 (NVA237 25 ug/placebo/NVA237 50 ug)

    Treatment sequence: NVA 237 25 ug, placebo and 50 ug

    Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo

  • Other
    5 (placebo/NVA237 50 ug/ NVA237 25 ug)

    Treatment sequence: Placebo, NVA237 50 ug and 25 ug

    Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo

  • Other
    6 (placebo/ NVA237 25 ug/NVA237 50 ug)

    Treatment sequence: placebo, NVA237 25 ug and 50 ug

    Drug: NVA237 (glycopyrronium bromide) · Drug: Placebo

Interventions

  • In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

  • DrugPlacebo

    In each treatment arm, patient will receive placebo

06

What researchers measure

Primary outcomes

  1. Trough FEV1 After One Week of Treatment, Point Estimate

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the respective treatment period. Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period. For the primary efficacy variable, trough FEV1 is the mean of two measurements taken at 23h 15 min and 23h 45 min post dose.

    Time frame: Following 1 week of treatment

Secondary outcomes

  1. FEV1 AUC (5 Min-1 h) After One Week of Treatment

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-1h)

    Time frame: Following 1 week of treatment

  2. FEV1 AUC (5 Min-4 h) After One Week of Treatment

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-4h)

    Time frame: Following 1 week of treatment

  3. FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day AUC (5 min - 23 h 45 min)

    Time frame: Following 1 week of treatment

  4. Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Peak FEV1 following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The peak effect following 1 week of treatment was defined as the maximum FEV1 during the first 4 hour on that day.

    Time frame: Following 1 week of treatment

  5. Trough Forced Vital Capacity (FVC) After 1 Week of Treatment

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FVC following 1 week of treatment in respective treatment period. Trough Forced Vital Capacity (FVC) following 7 Days. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry

    Time frame: Following 1 week of treatment

  6. Percent Change From Baseline in FEV1/FVC Ratio

    To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1/FVC ratio following 1 week of treatment in respective treatment period

    Time frame: Following 1 week of treatment

  7. Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period

    A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value

    Time frame: Following 1 week of treatment

  8. Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment

    A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits. LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates

    Time frame: Following 1 week of treatment

  9. Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment

    A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs.

    Time frame: Following 1 week of treatment

07

Results

Posted Jan 16, 2019

Participant flow

Participant flow — Overall Study
Milestone1(NVA237 50 ug/NVA237 25 ug/Placebo)2(NVA237 50 ug/Placebo/NVA237 25 ug)3 (NVA237 25 ug/NVA237 50 ug/Placebo)4 (NVA237 25 ug/Placebo/NVA237 50 ug)5 (Placebo/NVA237 50 ug/ NVA237 25 ug)6 (Placebo/ NVA237 25 ug/NVA237 50 ug)
Started242525242525
Completed222425242425
Not completed210010
Withdrew: Adverse event110000
Withdrew: Subject/guardian decision100000
Withdrew: Non-compliance with study treatment000010

Outcome measures

PrimaryTrough FEV1 After One Week of Treatment, Point Estimate

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared to placebo in terms of trough FEV1 (mean of 23h 15 min and 23 h 45 min post -dose) following 1 week of treatment in the respective treatment period. Trough FEV1 was assessed by performing spirometry measurements in the clinic for each treatment period. For the primary efficacy variable, trough FEV1 is the mean of two measurements taken at 23h 15 min and 23h 45 min post dose.

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Liters
Trough FEV1 After One Week of Treatment, Point Estimate
LitersNVA237 50 ugNVA237 25 ugPlacebo
Trough FEV1 After One Week of Treatment, Point Estimate2.392 ± 0.02492.392 ± 0.02502.303 ± 0.0247
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.089 · 95% CI 0.047 to 0.132
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.090 · 95% CI 0.047 to 0.132
SecondaryFEV1 AUC (5 Min-1 h) After One Week of Treatment

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-1h)

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Liters
FEV1 AUC (5 Min-1 h) After One Week of Treatment
LitersNVA237 50 ugNVA237 25 ugPlacebo
FEV1 AUC (5 Min-1 h) After One Week of Treatment2.489 ± 0.02262.492 ± 0.02282.324 ± 0.0227
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.165 · 95% CI 0.127 to 0.203
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.168 · 95% CI 0.129 to 0.206
SecondaryFEV1 AUC (5 Min-4 h) After One Week of Treatment

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 5min-4h)

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Liters
FEV1 AUC (5 Min-4 h) After One Week of Treatment
LitersNVA237 50 ugNVA237 25 ugPlacebo
FEV1 AUC (5 Min-4 h) After One Week of Treatment2.522 ± 0.02232.525 ± 0.02242.346 ± 0.0223
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.176 · 95% CI 0.141 to 0.212
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.179 · 95% CI 0.144 to 0.215
SecondaryFEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Standardized FEV1 AUC following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day AUC (5 min - 23 h 45 min)

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Liters
FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment
LitersNVA237 50 ugNVA237 25 ugPlacebo
FEV1 AUC (5 Min - 23 h 45 Min) After One Week of Treatment2.443 ± 0.02262.450 ± 0.02272.304 ± 0.0226
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.139 · 95% CI 0.106 to 0.173
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.146 · 95% CI 0.112 to 0.179
SecondaryPeak FEV1 During 4 Hours Post-dose After 1 Week of Treatment

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of Peak FEV1 following 1 week of treatment in the respective treatment period. FEV1 was measured with spirometry conducted according to internationally accepted standards. The peak effect following 1 week of treatment was defined as the maximum FEV1 during the first 4 hour on that day.

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Liters
Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment
LitersNVA237 50 ugNVA237 25 ugPlacebo
Peak FEV1 During 4 Hours Post-dose After 1 Week of Treatment2.621 ± 0.02282.630 ± 0.02292.457 ± 0.0228
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.164 · 95% CI 0.127 to 0.201
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 0.174 · 95% CI 0.137 to 0.211
SecondaryTrough Forced Vital Capacity (FVC) After 1 Week of Treatment

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FVC following 1 week of treatment in respective treatment period. Trough Forced Vital Capacity (FVC) following 7 Days. FVC is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Liters
Trough Forced Vital Capacity (FVC) After 1 Week of Treatment
LitersNVA237 50 ugNVA237 25 ugPlacebo
Trough Forced Vital Capacity (FVC) After 1 Week of Treatment3.509 ± 0.02683.530 ± 0.02693.472 ± 0.0267
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = 0.079 · Linear mixed model (lmm): 0.036 · 95% CI -0.004 to 0.077
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = 0.006 · Linear mixed model (lmm): 0.058 · 95% CI 0.017 to 0.099
SecondaryPercent Change From Baseline in FEV1/FVC Ratio

To evaluate the bronchodilator effects of NVA237 (25 ug and 50 ug) compared with placebo in terms of FEV1/FVC ratio following 1 week of treatment in respective treatment period

Time frame:
Following 1 week of treatment
Reported as:
Mean · Percent change
Percent Change From Baseline in FEV1/FVC Ratio
Percent changeNVA237 50 ugNVA237 25 ugPlacebo
Percent Change From Baseline in FEV1/FVC Ratio0.018 ± 0.04210.016 ± 0.04380.003 ± 0.0398
SecondaryMean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period

A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · L/min
Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period
L/minNVA237 50 ugNVA237 25 ugPlacebo
Mean Morning Peak Expiratory Flow (PEF) Following the 1-week Treatment Period395.09 ± 2.948393.87 ± 2.962369.58 ± 2.958
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 25.51 · 95% CI 19.22 to 31.79LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 24.29 · 95% CI 17.99 to 30.59
SecondaryMean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment

A Peak Expiratory Flow (PEF) meter was distributed to patients at Visit 1, to be used to measure PEF twice-daily as directed. During the Screening and Treatment Periods, PEF was measured in the morning and evening every day. the morning PEF was performed within 15 minutes after waking, and the evening PEF approximately 12 hours later. Patients were encouraged to perform morning and evening PEF measurements before the use of any LABA or rescue medication. The highest of 3 values was recorded as the daily personal best. The personal best was used to calculate the mean morning PEF and mean evening PEF value collected between assessment Visits. LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · L/min
Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment
L/minNVA237 50 ugNVA237 25 ugPlacebo
Mean Evening Peak Expiratory Flow Rate (PEF) Following 1-week Treatment409.66 ± 2.928408.08 ± 2.934378.72 ± 2.949
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 30.95 · 95% CI 25.07 to 36.82LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = <0.001 · Linear mixed model (lmm): 29.37 · 95% CI 23.47 to 35.26LS Mean of change from baseline in mean morning PEF is calculated with the ANCOVA model using treatment, stratification group, dosing schedule, gender, center grouping, smoking status, and baseline mean morning PEF as covariates
SecondaryMean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment

A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs.

Time frame:
Following 1 week of treatment
Reported as:
Least squares mean · Puffs/day
Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment
Puffs/dayNVA237 50 ugNVA237 25 ugPlacebo
Mean Daily Number of Puffs of Rescue Medication During 1 Week of Treatment0.98 ± 0.0941.02 ± 0.0941.13 ± 0.094
Statistical analysis
  • NVA237 50 ug vs Placebo · Linear Mixed Model · p = 0.053 · Linear mixed model (lmm): -0.15 · 95% CI -0.31 to 0.00
  • NVA237 25 ug vs Placebo · Linear Mixed Model · p = 0.163 · Linear mixed model (lmm): -0.11 · 95% CI -0.27 to 0.05

Adverse events

Collected over Following 1 week of treatment. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237 50 ug0/147 (0%)1/147 (0.7%)10/147 (6.8%)
NVA237 25 ug1/146 (0.7%)1/146 (0.7%)11/146 (7.5%)
Placebo0/146 (0%)0/146 (0%)11/146 (7.5%)
Most frequent serious events
Most frequent serious events
EventNVA237 50 ugNVA237 25 ugPlacebo
Completed suicidePsychiatric disorders0/1471/1460/146
Patellofemoral pain syndromeMusculoskeletal and connective tissue disorders1/1470/1460/146
Most frequent other events
Most frequent other events
EventNVA237 50 ugNVA237 25 ugPlacebo
HeadacheNervous system disorders5/1472/1462/146
NasopharyngitisInfections and infestations2/1471/1463/146
Upper respiratory tract infectionInfections and infestations1/1473/1461/146
Muscle strainInjury, poisoning and procedural complications1/1470/1462/146
DizzinessNervous system disorders1/1470/1462/146
AsthmaRespiratory, thoracic and mediastinal disorders0/1472/1460/146
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/1472/1460/146
Dermatitis contactSkin and subcutaneous tissue disorders0/1472/1461/146

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Mean47.3 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female75
Male73
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian16
Native Hawaiian or Other Pacific Islander0
Black or African American12
White120
More than one race0
Unknown or Not Reported0
08

Study locations

21 sites
  • Novartis Investigative Site
    North Dartmouth, Massachusetts 02747, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Skillman, New Jersey 08558, United States
  • Novartis Investigative Site
    Raleigh, North Carolina 27607, United States
  • Novartis Investigative Site
    Medford, Oregon 97504, United States
  • Novartis Investigative Site
    El Paso, Texas 79903, United States
  • Novartis Investigative Site
    Erpent, 5100, Belgium
  • Novartis Investigative Site
    Hasselt, 3500, Belgium
  • Novartis Investigative Site
    Mechelen, 2800, Belgium
  • Novartis Investigative Site
    Berlin, 10119, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Grosshansdorf, 22927, Germany
  • Novartis Investigative Site
    Lubeck, 23552, Germany
  • Novartis Investigative Site
    Wiesbaden, 65187, Germany
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 169-0073, Japan
  • Novartis Investigative Site
    Toshima-ku, Tokyo 171-0014, Japan
  • Novartis Investigative Site
    Daugavpils, LVA LV-5417, Latvia
  • Novartis Investigative Site
    Riga, LV 1002, Latvia
  • Novartis Investigative Site
    Riga, LV-1038, Latvia
  • Novartis Investigative Site
    Klaipeda, LT-92231, Lithuania
  • Novartis Investigative Site
    Klaipeda, LT-92288, Lithuania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Dec 2017, 7 months.

Results were first posted in Jan 2019, 1 year after primary completion.

Of 14 phase 2/3 interventional studies under Asthma, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2017
First posted
May 3, 2017
StartActual
May 4, 2017
Primary completionActual
Dec 29, 2017
CompletionActual
Dec 29, 2017
Results first posted
Jan 16, 2019
Last update
Jan 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03137784
Responsible party
Sponsor
First posted
May 3, 2017
Start date
May 4, 2017
Primary completion
Dec 29, 2017
Completion
Dec 29, 2017
Results posted
Jan 16, 2019
Last update
Jan 16, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion